E
Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
E
Sell
3/5/2025Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 3/5/2025 due to a substantial decline in the total return index and volatility index.
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 3/5/2025 due to a substantial decline in the total return index and volatility index.
D
Sell
12/27/2024Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 12/27/2024 due to an increase in the valuation index.
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 12/27/2024 due to an increase in the valuation index.
E
Sell
12/12/2024Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 12/12/2024 due to a decline in the volatility index.
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 12/12/2024 due to a decline in the volatility index.
D
Sell
9/12/2024Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 9/12/2024 due to an increase in the volatility index and total return index.
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 9/12/2024 due to an increase in the volatility index and total return index.
E
Sell
8/28/2024Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 8/28/2024 due to a decline in the volatility index.
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 8/28/2024 due to a decline in the volatility index.
D
Sell
1/22/2024Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index and total return index.
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index and total return index.
E
Sell
1/5/2024Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 1/5/2024 due to a decline in the valuation index and volatility index.
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 1/5/2024 due to a decline in the valuation index and volatility index.
D
Sell
12/18/2023Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and total return index.
Keros Therapeutics, Inc. (KROS) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and total return index.
E
Sell
11/30/2023Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 11/30/2023 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 10.22% from -$30.83M to -$33.98M, earnings per share declined from -$1.267 to -$1.3294, and EBIT declined 4.7% from -$41.34M to -$43.28M.
Keros Therapeutics, Inc. (KROS) was downgraded to E+ from D- on 11/30/2023 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 10.22% from -$30.83M to -$33.98M, earnings per share declined from -$1.267 to -$1.3294, and EBIT declined 4.7% from -$41.34M to -$43.28M.
D
Sell
3/14/2023Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index. Earnings per share declined from -$0.9201 to -$1.0875, and EBIT declined 14.24% from -$27.98M to -$31.96M.
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index. Earnings per share declined from -$0.9201 to -$1.0875, and EBIT declined 14.24% from -$27.98M to -$31.96M.
D
Sell
2/23/2023Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and valuation index.
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and valuation index.
D
Sell
2/8/2023Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
9/30/2022Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 9/30/2022 due to an increase in the valuation index and volatility index.
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 9/30/2022 due to an increase in the valuation index and volatility index.
D
Sell
8/18/2022Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 8/18/2022 due to a large decline in the solvency index, total return index and volatility index. The quick ratio declined from 19.64 to 13.96.
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 8/18/2022 due to a large decline in the solvency index, total return index and volatility index. The quick ratio declined from 19.64 to 13.96.
D
Sell
5/5/2022Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index, total return index and volatility index.
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index, total return index and volatility index.
D
Sell
4/20/2022Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
11/23/2021Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Keros Therapeutics, Inc. (KROS) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and valuation index. EBIT declined 29.96% from -$15.54M to -$20.2M, and earnings per share declined from -$0.6703 to -$0.8688.
Keros Therapeutics, Inc. (KROS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and valuation index. EBIT declined 29.96% from -$15.54M to -$20.2M, and earnings per share declined from -$0.6703 to -$0.8688.
D
Sell
9/9/2021Downgrade
Keros Therapeutics, Inc. (KROS) was downgraded to D from D+ on 9/9/2021 due to a decline in the volatility index, total return index and valuation index.
Keros Therapeutics, Inc. (KROS) was downgraded to D from D+ on 9/9/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
8/25/2021Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D+ from D on 8/25/2021 due to an increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.6838 to -$0.6703, and EBIT increased 1.45% from -$15.77M to -$15.54M.
Keros Therapeutics, Inc. (KROS) was upgraded to D+ from D on 8/25/2021 due to an increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.6838 to -$0.6703, and EBIT increased 1.45% from -$15.77M to -$15.54M.
D
Sell
3/18/2021Upgraded
Keros Therapeutics, Inc. (KROS) was upgraded to D from E on 3/18/2021 due to an increase in the total return index.
Keros Therapeutics, Inc. (KROS) was upgraded to D from E on 3/18/2021 due to an increase in the total return index.
E
Sell
8/14/2020None
Keros Therapeutics, Inc. (KROS) was downgraded to E from U on 08/14/2020.
Keros Therapeutics, Inc. (KROS) was downgraded to E from U on 08/14/2020.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
